Axpaxli’s Superior SOL-1 Phase 3 Data Support Buy Rating and Constructive Outlook on Ocular Therapeutix

In a report released today, Serge Belanger from Needham reiterated a Buy rating on Ocular Therapeutix, with a price target of $18.00.

Serge Belanger has given his Buy rating due to a combination of factors tied to Axpaxli’s latest phase 3 SOL-1 results and their strategic implications for Ocular Therapeutix. The more granular data shown at the Macula Society meeting reinforce that Axpaxli delivers consistently better outcomes than Eylea at 6, 9, and 12 months, including stronger control of retinal fluid and a safety profile that aligns with other retinal therapies.

Belanger also notes that the SOL-1 design and rescue-free criteria generated compelling clinical evidence in a patient population not often explored in late-stage retinal studies, strengthening the case for a differentiated label. He expects Axpaxli to secure approval with a superiority claim and a 6–12 month dosing interval, positioning it as a distinctly attractive option versus current and emerging anti-VEGF agents and supporting a constructive outlook on OCUL shares.

Belanger covers the Healthcare sector, focusing on stocks such as Viridian Therapeutics, Ocular Therapeutix, and Cytokinetics. According to TipRanks, Belanger has an average return of 11.3% and a 47.80% success rate on recommended stocks.

In another report released today, Piper Sandler also maintained a Buy rating on the stock with a $31.00 price target.